Allogeneic transplantation is a curative treatment for patients with therapy related myelodysplastic syndrome despite higher-risk features.

- 266 patients with diagnosis of MDS who received alloHCT
- Analysis of clinical characteristics and outcomes
- Next generation sequencing of 72 genes

5-year overall survival
- t-MDS: 49.9%
- MDS de novo: 53.9%

Intermediate-2/High IPSS
- t-MDS: 59.7%
- MDS de novo: 43.7%

High-risk karyotypes
- t-MDS: 61.2%
- MDS de novo: 30.7%

- t-MDS: 30% mutations in TP53
- 48% mutations in high-risk genes (EZH2, ETV6, RUNX1, ASXL1)

No impact:
- overall survival
- relapse-free survival

Aldoss et al., Haematologica, 2017